The Nifty has added three sessions in a row off Monday's low, closing today at 23,346, up a third straight day. Advance-decline ratios have swung hard positive, near a 30-session high, and the share of stocks above their 20-day average has jumped from 23% to 36% in three sessions. On the surface this reads like a recovery. Underneath, the share of stocks actually in Stage 2 fell again today to just under 32%, the lowest reading in a month - so the bounce is happening while the pool of genuine advancing setups keeps shrinking.
A rally in breadth counts, not in stage structure
The gap is the story. Over the last five sessions, 61 stocks have slipped from Stage 2 into Stage 3 against only 27 being promoted from Stage 1 into Stage 2 - net transitions have now been negative for seventeen straight sessions. That is the churn of names topping out faster than new ones are being built, even as price and short-term breadth recover. Fifty-two-week highs minus lows is still negative for a sixth straight session, at minus 42 today, though that is a big improvement from minus 201 earlier in the week. Death crosses (8) now edge out golden crosses (7) for the first time in this stretch. None of this says the bounce is fake. It says the underlying trend map has not turned yet - the regime read has been stuck at neutral-to-down for thirteen sessions running, and today's rally has not been enough to shift it.
Energy holds up, IT does not
Ten of eleven sectors closed higher, led by Industrials, Utilities and Communication Services, all up more than 1.5%. Energy was the lone red sector, down 0.36%, yet it is the only one that has been building Stage 2 participation through this entire drawdown - its Stage-2 share sits above 50%, up sixteen points over the last month, concentrated in oil & gas equipment and exploration names. Information Technology is the opposite case: worst relative-strength score in the sector table, red again today, and its Stage-2 share has been shrinking for a month. If you are hunting for where sellers have genuinely lost interest, it is not IT.
Where the setups sit
Among names still early in their move and not yet extended, Alembic and Asian Hotels (North) top today's list, both scoring 8.3, alongside Hatsun Agro and a cluster of pharma and industrial names. On the other end, the highest-scoring trends - Fineotex Chemical, Raymond, Bhageria Industries among them - have already run hard and are not fresh entries, just a read on where momentum currently sits. Given the transition churn described above, treat any Stage-2 name today with more scrutiny than usual on how early it actually is in its base.
| Stock | Sector | Setup | % 1D |
|---|---|---|---|
| Alembic Ltd | Health Care | 8.3 | -0.1% |
| Asian Hotels (North) Ltd | Consumer Discretionary | 8.3 | -0.2% |
| Hatsun Agro Product Ltd | Consumer Staples | 8.0 | -3.6% |
| Anuh Pharma Ltd | Health Care | 8.0 | -0.2% |
| Pitti Engineering Ltd | Industrials | 7.9 | +1.3% |
| Gujarat Themis Biosyn Ltd | Health Care | 7.8 | +1.7% |
| Ratnamani Metals and Tubes Ltd | Industrials | 7.8 | +5.8% |
| Hindustan Oil Exploration Company Ltd | Energy | 7.8 | -0.4% |
| Sector | 1D | 1M | 3M | RS | Stage 2 |
|---|---|---|---|---|---|
| Industrials | +2.3% | -1.2% | -0.7% | 68 | 27% |
| Utilities | +1.9% | -1.2% | -8.7% | 57 | 15% |
| Communication Services | +1.7% | +0.2% | +5.6% | 62 | 23% |
| Real Estate | +1.3% | -3.6% | +5.6% | 54 | 26% |
| Materials | +1.3% | -1.3% | -0.7% | 64 | 36% |
| Financials | +1.2% | -1.6% | -1.9% | 59 | 31% |
| Health Care | +1.0% | +2.0% | +10.1% | 72 | 47% |
| Consumer Discretionary | +0.9% | -2.3% | +6.3% | 60 | 34% |
| Consumer Staples | +0.1% | -3.3% | -5.2% | 45 | 34% |
| Energy | -0.4% | -3.7% | -2.7% | 57 | 52% |
| Information Technology | -0.9% | -4.4% | +3.1% | 44 | 24% |
Work the same data live: open the full stock screener, watch the live market dashboard, or check the market-timing read. New to the method? Start with the four stages.
Stage2Stocks is an educational stage-analysis screener. These wraps describe what the screen shows across NSE cash equities — they are not investment advice, recommendations, or buy/sell calls. Always do your own research.